Genetron Holdings Ltd. ADR (GTH): Price and Financial Metrics


Genetron Holdings Ltd. ADR (GTH): $16.46

0.07 (+0.43%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

GTH POWR Grades


  • Sentiment is the dimension where GTH ranks best; there it ranks ahead of 68.69% of US stocks.
  • GTH's strongest trending metric is Stability; it's been moving down over the last 47 weeks.
  • GTH's current lowest rank is in the Momentum metric (where it is better than 16.43% of US stocks).

GTH Stock Summary

  • GTH's went public 1.25 years ago, making it older than just 1.35% of listed US stocks we're tracking.
  • GTH's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of just 0.82% of US stocks.
  • Genetron Holdings Ltd's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -117.48%, greater than the shareholder yield of just 1.73% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Genetron Holdings Ltd are DOOO, ALIM, CLRO, POLA, and SRTS.
  • To check out Genetron Holdings Ltd's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001782594.

GTH Stock Price Chart Interactive Chart >

Price chart for GTH

GTH Price/Volume Stats

Current price $16.46 52-week high $31.54
Prev. close $16.39 52-week low $9.03
Day low $16.22 Volume 2,096,800
Day high $16.94 Avg. volume 349,263
50-day MA $15.23 Dividend yield N/A
200-day MA $19.13 Market Cap 1.46B

Genetron Holdings Ltd. ADR (GTH) Company Bio


Genetron Holdings, Ltd. engages in precision oncology. It provides cancer molecular profiling by using technologies in molecular biology and data science to transform cancer treatment. It products and services include diagnosis and monitoring through both LDT and IVD products. Its LDT portfolio consists of both specifically designed focused and comprehensive gene panel testing services. It also develops liver cancer early screening products. The company was founded by Si Zhen Wang, Hai Yan, and Wei Wu He in 2015 and is headquartered in Beijing, China.


GTH Latest News Stream


Event/Time News Detail
Loading, please wait...

GTH Latest Social Stream


Loading social stream, please wait...

View Full GTH Social Stream

Latest GTH News From Around the Web

Below are the latest news stories about Genetron Holdings Ltd that investors may wish to consider to help them evaluate GTH as an investment opportunity.

Genetron Health Unveils 13 Cancer Research findings at ESMO Congress 2021

BEIJING, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that it has partnered with a consortium of 14 top Chinese hospitals to release 13 key research findings at the ESMO 2021 Congress, hosted by the European Society for Medical Oncology. The fi

Yahoo | September 16, 2021

Genetron Added to FTSE Russell Global Equity Index Series

BEIJING, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (Genetron Health or the Company, NASDAQ: GTH), today announced that Genetron will be added to the below FTSE Global Equity Index Series ("GEIS"), following FTSE''s most recent quarterly review. These inclusions will become effective after the market close on Friday, September 17, 2021:

Intrado Digital Media | September 3, 2021

Genetron Healths Co-Founder and Chief Scientific Officer Awarded International Prize for Translational Neuroscience 2021

BEIJING, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (Genetron Health or the Company, NASDAQ:GTH), a leading precision oncology platform company in China that specializes in molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that its Co-Founder and Chief Scientific Officer, Dr. Hai Yan, was awarded the International Prize for Translational Neuroscience 2021. Awarded by the Gertrud Reemtsma Foundation through the Max Planck Society, the prize is one of the most prominent awards in neuroscience and recognizes individuals who have made outstanding and original contributions to the understanding of neurobiology and neurological disease. The ceremony took place at the Max-Planck-Institute in Cologne, Germany, on A...

Intrado Digital Media | August 30, 2021

Genetron Health’s Co-Founder and Chief Scientific Officer Awarded International Prize for Translational Neuroscience 2021

BEIJING, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ:GTH), a leading precision oncology platform company in China that specializes in molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that its Co-Founder and Chief Scientific Officer, Dr. Hai Yan, was awarded the International Prize for Translational Neuroscience 2021. Awarded by the Gertrud Reemtsma Foundation through the M

Yahoo | August 30, 2021

Does This Valuation Of Genetron Holdings Limited (NASDAQ:GTH) Imply Investors Are Overpaying?

In this article we are going to estimate the intrinsic value of Genetron Holdings Limited ( NASDAQ:GTH ) by projecting...

Yahoo | August 24, 2021

Read More 'GTH' Stories Here

GTH Price Returns

1-mo 37.28%
3-mo -22.21%
6-mo -12.54%
1-year 43.88%
3-year N/A
5-year N/A
YTD 17.57%
2020 N/A
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7222 seconds.